The advent of sulfanilamide has revolutionized the treatment of meningitis caused by Streptococcus haemolyticus beta. Previously the disease had a mortality of about 97 per cent; this drug is said to have reduced the mortality to about 20 per cent. Endeavors now are aimed toward the establishment of the proper dosage and the development of the best method of administering the drug.
There are two objectives in the treatment of the meningitides: the saving of life and the prevention of the sequelae which often develop. If one investigates a series of persons who four or five years previously had cerebrospinal meningitis which was treated by serum, one finds a high percentage of serious sequelae, such as jacksonian epilepsy, deafness and severe headaches. These sequelae are caused by deformity of the pia-arachnoid which results from repair of the acute inflammation or by internal hydrocephalus due to partial or complete block in